Drug Development Prospecting: Will Sirtris' Pipeline Pay Dividends at FDA?
This article was originally published in RPM Report
Executive Summary
GlaxoSmithKline went out on a limb by paying $720 million for Sirtris' relatively untested enzyme technology. How FDA evaluates the first-in-class therapy will determine whether GSK was pound wise or pound foolish. Two former FDA reviewers weigh in on how the company can make the most from its investment.